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Abstract
Aims/hypothesis Previous studies have found an association
between serum magnesium and incident diabetes; however,
this association may be due to reverse causation, whereby
diabetes may induce urinary magnesium loss. In contrast, in
prediabetes (defined as impaired fasting glucose), serum
glucose levels are below the threshold for urinary magnesium
wasting and, hence, unlikely to influence serum magnesium
levels. Thus, to study the directionality of the association
between serummagnesium levels and diabetes, we investigated
its association with prediabetes. We also investigated whether
magnesium-regulating genes influence diabetes risk through
serummagnesium levels. Additionally, we quantified the effect
of insulin resistance in the association between serum
magnesium levels and diabetes risk.
Methods Within the population-based Rotterdam Study, we
used Cox models, adjusted for age, sex, lifestyle factors,
comorbidities, kidney function, serum levels of electrolytes
and diuretic use, to study the association between serum
magnesium and prediabetes/diabetes. In addition, we
performed two mediation analyses: (1) to study if common
genetic variation in eight magnesium-regulating genes
influence diabetes risk through serum magnesium levels;
and (2) to quantify the proportion of the effect of serum
magnesium levels on diabetes that is mediated through insulin
resistance (quantified by HOMA-IR).
Results A total of 8555 participants (mean age, 64.7 years;
median follow-up, 5.7 years) with normal glucose levels
(mean±SD: 5.46±0.58 mmol/l) at baseline were included.
A 0.1 mmol/l decrease in serummagnesium level was associa-
ted with an increase in diabetes risk (HR 1.18 [95% CI 1.04,
1.33]), confirming findings from previous studies. Of interest,
a similar association was found between serum magnesium
levels and prediabetes risk (HR 1.12 [95% CI 1.01, 1.25]).
Genetic variation in CLDN19, CNNM2, FXYD2, SLC41A2,
and TRPM6 significantly influenced diabetes risk (p<0.05),
and for CNNM2, FXYD2, SLC41A2 and TRPM6 this risk was
completely mediated by serum magnesium levels. We found
that 29.1% of the effect of serum magnesium levels on
diabetes was mediated through insulin resistance, whereas
for prediabetes 13.4% was mediated through insulin
resistance.
Conclusions/interpretation Low serum magnesium levels are
associated with an increased risk of prediabetes and this
increased risk is similar to that of diabetes. Furthermore,
common variants in magnesium-regulating genes modify
diabetes risk through serum magnesium levels. Both findings
support a potential causal role of magnesium in the
development of diabetes, where the hypothesised pathway is
partly mediated through insulin resistance.
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Introduction
The prevalence of diabetes mellitus is increasing worldwide
and recent estimates indicate that one out of three people will
develop diabetes during their life [1]. This underlines the
importance of prevention and, therefore, the need to identify
modifiable risk factors [1]. One potential modifiable risk
factor that has emerged recently is magnesium. Magnesium
is a co-factor in several pathways, including glucose transport,
insulin sensitivity and insulin secretion [2–4], providing a
molecular basis for its involvement in the pathogenesis of
diabetes mellitus.
Several population-based cohort studies have identified
associations between magnesium intake and incident diabetes,
incident prediabetes (defined as impaired fasting glucose) and
progression of prediabetes to diabetes [5–9]. However, the
association between magnesium intake and diabetes may be
explained by an overall healthier eating pattern, since healthy
foods, such as green leafy vegetables, are usually magnesium
rich. Therefore, magnesium intake could be a proxy for a
healthy diet rather than an independent risk factor [10, 11].
These limitations may be partially addressed by using serum
magnesium levels instead of magnesium intake as a determi-
nant for association analyses. Indeed, lower serummagnesium
levels have also been associated with diabetes [12, 13].
A remaining issue regarding the association between serum
magnesium levels and diabetes is the possibility of reverse
causality. Patients with diabetes show increased urinary
magnesium loss, caused by hyperglycaemia, hyperfiltration
or a direct effect of insulin on magnesium channels in the
kidney [14]. In contrast, in prediabetes, serum glucose levels
are below the threshold for urinary magnesium wasting and,
hence, unlikely to influence serum magnesium levels.
In the current study, we aimed to explore the directionality
of the relationship between serum magnesium levels and
diabetes in a large population-based cohort with adjudicated
endpoints and long-term follow-up. To do so, we studied
the relationship between serum magnesium levels and
prediabetes. An association between serum magnesium levels
and this precursor stage of diabetes is not expected if low
serum magnesium is caused by long-standing diabetes. To
further address the directionality of the association between
serum magnesium and diabetes, we investigated whether
magnesium-regulating genes are associated with diabetes risk.
Finally, we quantified the role of insulin resistance as a
potential pathway by which serum magnesium levels
influence diabetes risk.
Methods
Study design, setting and population This study was
embedded within the Rotterdam Study, a prospective
population-based cohort study, ongoing since 1990 in a
suburb of Rotterdam, the Netherlands. The rationale and
design of this study have been described elsewhere [15]. In
summary, the original cohort was extended with a second
cohort in 2000 and a third cohort in 2006, resulting in a total
study population of 14,926 participants, aged 45 years and
older. Participants are asked to participate in follow-up
examinations every 4–5 years. The Rotterdam Study complies
with the Declaration of Helsinki and has been approved by the
Medical Ethics Committee of the Erasmus Medical Center
and by the Dutch Ministry of Health, Welfare and Sport,
implementing the Wet Bevolkingsonderzoek: ERGO
(Population Study Act: Rotterdam Study). All participants
provided written informed consent to participate in the study
and to obtain information from their physicians.
Measurements Magnesium was measured within blood
collections from the third visit of the first cohort (1997–1999),
and the baseline visits of the second (2000–2001) and the
third (2006–2008) cohort. These visits are similar in design
and methods for data collection. Magnesium (mmol/l) was
measured in serum by the Department of Clinical
Chemistry of the Erasmus Medical Center (Rotterdam,
the Netherlands). All measurements were carried out using
a colourimetric endpoint method and the Roche/Hitachi
Cobas c501 Analyzer (Roche Diagnostics, Indianapolis,
IN, USA). The CV for repeatability was 0.8% and the
CV for intermediate precision was 1.4–1.7%.
Serum calcium, serum potassium, total cholesterol,
HDL-cholesterol and serum creatinine were measured at the
same visit as serum magnesium (Roche Diagnostics,
Indianapolis, IN, USA). Serum calcium was measured using
a photometric endpoint method, with a CV for repeatability of
0.4–2.0% and a CV for intermediate precision of 0.9–2.5%.
Serum potassium was measured quantitatively with
ion-selective electrodes, with a CV for repeatability of
0.3–0.6% and a CV for intermediate precision of 0.7–1.6%.
eGFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation [16]. Total
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cholesterol and HDL-cholesterol were measured using an
enzymatic colourimetric approach.
Measurement and assessment of anthropometrics has been
described previously [15]. Briefly, blood pressure was
measured twice during study visits and the average was
calculated. Information on smoking habits and alcohol
consumption was obtained during a home interview; smoking
habits were categorised as non-smoker, former smoker and
current smoker. Alcohol use was categorised into two
categories: yes or no [15]. Information on prevalent stroke
and coronary heart disease was determined on the date that
blood was drawn from the participants via linkage with
general practitioners working in the study area, and
adjudicated by two medical doctors and a neurologist or
cardiologist in case of disagreement [17]. Information
regarding the use of diuretics was derived from linkage to
pharmacy dispensing records [15]. Serum insulin was
measured using an immunoassay (Roche Diagnostics) and
for the majority of all participants (96.8%) fasting insulin
levels were available. Insulin resistance was assessed using
HOMA-IR values [18]. We used the natural logarithm (loge)
of HOMA-IR levels +1 to account for non-normal distribution.
Genetic analysisWe used a candidate gene approach to select
11 magnesium-regulating genes, which were hypothesized to
play a role in the development of diabetes (see electronic
supplementary material [ESM] Table 1). Lead single
nucleotide polymorphisms (SNPs) in these magnesium
regulating genes were identified from the literature [19–21].
Our goal was to select common genetic variations for our
analysis; therefore, we only included SNPs with a minor allele
frequency >10%, resulting in the following genes and
corresponding SNPs being selected: TRPM7 (rs8042919),
TRPM6 (rs2274924), SLC41A1 (rs823154), SLC41A2
(rs2463021), CNNM2 (rs3740393), CLDN19 (rs719676),
CLDN16 (rs9990270) and FXYD2 (rs948100). Genotyping
was carried out using the Illumina 550 duo and Illumina 610
quad BeadChip (Illumina, San Diego, CA, USA). For all
participants that were included in this study, SNPs passed
genotyping quality control, had a call rate >98% and had a
Hardy–Weinberg p value >1×10−6. Data were imputed to the
1000 Genomes reference panel (phase 1, version 3) using
MACH version 1.0.15/1.0.16 [22, 23]. Imputation quality
for all SNPs was high (>0.97).
Assessment of outcomes In this study, we excluded prevalent
cases of diabetes. Incident cases of prediabetes and type 2
diabetes were ascertained through active follow-up using
general practitioners’ records, hospital discharge letters and
glucose measurements from Rotterdam Study visits [1].
Diabetes and prediabetes were defined according to the recent
WHO guidelines [24]. Briefly, diabetes was defined as fasting
blood glucose ≥7.0 mmol/l, a non-fasting blood glucose
≥11.1 mmol/l (in the absence of fasting samples) or the use
of blood glucose lowering medication (including oral blood
glucose lowering medication such as metformin). Prediabetes
was defined as a fasting blood glucose between 6.0 and
7.0 mmol/l or a non-fasting blood glucose between 7.7 and
11.1 mmol/l (in the absence of fasting samples). For the
majority of all participants (96.8%) fasting blood glucose
samples were available and for the remaining, a random
non-fasting blood glucose level was used. Information
regarding the use of blood glucose lowering medication was
derived from both structured home interviews and linkage to
pharmacy dispensing records [15]. All outcomes of
prediabetes and diabetes were adjudicated by two independent
study physicians. In case of disagreement, consensus was
sought with an endocrinologist. Follow-up data was complete
until 1 January 2012.
Statistical analyses Means, SD and percentages with
frequency were used to report continuous and discrete
variables. The relationship between serum magnesium levels
and prediabetes was modelled using restricted cubic splines,
using three knots, and was found to be linear. Therefore, we
used serum magnesium as a continuous variable in
multivariate Cox proportional hazards regression models to
examine the relationship of serum magnesium levels with
incident diabetes and prediabetes. Additionally, we studied
the relationship between hypomagnesaemia (defined as serum
magnesium ≤0.72 mmol/l) and incident diabetes and
prediabetes. Follow-up time was calculated from the date that
blood was drawn until the date of death, loss to follow-up or
end of the study. The proportional hazards assumption was
tested by plotting the log10 minus log10 survival curve and
visually examining the curves, with no evidence that the
assumption was violated [25].
We performed two mediation analyses: (1) quantifying the
role of insulin resistance in the association of serum
magnesium levels with diabetes and prediabetes; (2) to study
if genetic variation in magnesium regulating genes associates
with diabetes and prediabetes through serum magnesium
levels. To do so, we used the logistic model as reported by
Baron and Kenny [26]. We calculated the standardised
indirect effect, which is a measure for the degree of mediation
through the mediator, and tested for significance using
bootstrapping procedures (n=1000) [27]. For all analyses on
diabetes we used a study population including all participants
without diabetes at baseline; for the analyses on prediabetes
we included all participants with normal glucose levels at
baseline.
Missing data in covariables (present in 0.0–1.4%) were
handled by single imputation using an expectation–
maximization algorithm [28]. All analyses were repeated on
complete cases to check for potential differences. With the
exception of the baseline characteristics, results are reported
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for imputed data. We considered a two-sided p value <0.05 as
statistically significant. Data were analysed using SPSS
Statistics version 21.0 (IBM, Armonk, NY, USA) and R
version 3.1.2. (The R Foundation for Statistical Computing,
Vienna, Austria).
Sensitivity analyses To test the robustness of our findings, we
performed several sensitivity analyses. First, we repeated our
analysis on prediabetes using electrolytes other than
magnesium (sodium, potassium, calcium and phosphate), to
rule out that the observed association between serum
magnesium levels and prediabetes is caused by a coexisting
electrolyte disorder. In the second sensitivity analyses, we
studied whether participants without a separate diagnosis date
of prediabetes could have influenced our effect estimates. In
these individuals, both the diagnosis of prediabetes and
diabetes was regarded as being made on the same day, as no
separate date of prediabetes diagnosis could be determined.
Therefore, where the date of prediabetes diagnosis was
missing, we imputed this date and repeated the analysis on
prediabetes using these new dates. In the third sensitivity
analysis, we excluded all participants with an eGFR below
60 ml min−1 [1.73 m2]−1 to exclude the possibility that
impaired kidney function could have impacted our results. In
the fourth sensitivity analysis, we excluded all participants
with hypomagnesaemia and hypermagnesaemia to confirm
that our results were not driven by these extremes. In the final
sensitivity analysis, we studied if the association between
serum magnesium and diabetes risk could have been
explained by proton pump inhibitor use as proton pump
inhibi tors have been previously associated with
hypomagnesaemia [29].
Results
Baseline characteristics Our total study population
comprised 8555 participants (Fig. 1). Table 1 shows the
baseline characteristics of our study population. The mean
age was 64.7 years and 57.8% were women. Participants with
prevalent prediabetes more often had a history of smoking,
hypertension, coronary heart disease, and used diuretics more
often. The range of serum magnesium in the total population
was 0.34–1.17 mmol/l. For participants with normal glucose
levels at baseline, this range was 0.46–1.17 mmol/l, whilst for
participants with prediabetes at baseline, this range was
0.34–1.20 mmol/l.
Association between serummagnesium levels and incident
diabetes Among the 8555 participants without diabetes at
baseline, 806 cases of incident diabetes were identified over
a median follow-up of 6.7 years. Table 2 shows the association
between serum magnesium levels and incident diabetes. We
found that a 0.1 mmol/l decrease in serum magnesium levels
was associated with an increase in diabetes risk (HR 1.21
[95% CI 1.07, 1.37]). After adjustment for lifestyle factors,
comorbidities and other electrolytes this association persisted,
but was slightly attenuated (HR 1.18 [95% CI 1.04, 1.33]).
Participants with hypomagnesaemia had an increased diabetes
risk before and after adjustment for confounders (HR 2.12
[95% CI 1.38, 3.28] and HR 1.79 [95% CI 1.16, 2.77],
respectively). We found no evidence of effect modification
by sex (p for interaction=0.36).
Association between serummagnesium levels and incident
prediabetesAmong the 7209 participants with blood glucose
levels within the normal range (fasting blood glucose
<6.0 mmol/l or non-fasting blood glucose <7.7 mmol/l) at
baseline, 1120 cases of incident prediabetes were identified
over a median follow-up of 5.7 years. Table 2 shows the
association between serum magnesium levels and incident
prediabetes. We found that a 0.1 mmol/l decrease in serum
magnesium levels was associated with an increased risk of
prediabetes before adjustment (HR 1.14 [95% CI 1.02,
1.27]) and after adjustment (HR 1.12 [95% CI 1.01, 1.25])
for confounders. Participants with hypomagnesaemia had an
increased diabetes risk before adjustment for confounders
(HR 1.72 [95% CI 1.09, 2.71]). After adjustment for
confounders, this risk was attenuated and was no longer
statistically significant (HR 1.44 [95% CI 0.91, 2.27]). We
found no evidence of effect modification by sex (p for
interaction=0.18).
Genetic risk factors The selected common genetic variants
were mainly located in introns (ESM Table 1). For five SNPs
(rs719676, rs3740393, rs948100, rs2463021 and rs2274924),
we found a significant association with serum magnesium
levels (Table 3). For four SNPs (rs3740393, rs948100,
rs2463021 and rs2274924), we found an indirect effect on
diabetes risk. For rs719676, we found a significant direct
effect on diabetes risk (OR 0.84 [95% CI 0.74, 0.96]), but
no evidence that this effect was mediated through serum
magnesium levels. The same analysis was repeated on
prediabetes risk, but only a significant direct effect of
rs719676 on prediabetes was observed (OR 0.88 [95% CI
0.78, 0.98]). The other selected gene variants were not
significantly associated with prediabetes.
Association between serum magnesium levels and insulin
resistance The association between serum magnesium levels,
loge HOMA-IR levels and diabetes is shown in Fig. 2a. We
confirmed that serum magnesium levels were significantly
associated with loge HOMA-IR levels and also that loge
HOMA-IR levels were significantly associated with the risk
of diabetes. When studying the direct effect of serum
magnesium levels on the risk of diabetes adjusted for loge
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HOMA-IR levels, the effect estimates were attenuated and the
association was no longer statistically significant. The indirect
effect of serum magnesium levels on diabetes risk, as
mediated by loge HOMA-IR levels, was significant with an
odds ratio of 1.05 per 0.1 mmol/l decrease in serum magne-
sium levels. The calculated percentage of mediation was
29.1%. Fig. 2b shows the association between serum
magnesium levels, loge HOMA-IR levels and prediabetes.
We found that serum magnesium levels were significantly
associated with loge HOMA-IR levels, within this group and
that loge HOMA-IR levels were also significantly associated
with the risk of prediabetes, a finding similar to that of the
association with diabetes. For the association with prediabetes,
the calculated percentage of mediation was 13.4%.
Sensitivity analyses We found that, besides magnesium, no
other electrolyte was associated with the risk of prediabetes
(Table 4). For 235 participants, we did not have a separate date
for prediabetes diagnosis, therefore this date was imputed. For
25 participants, data were excluded from this sensitivity
analysis as the imputed prediabetes diagnosis date was before
serum magnesium measurement. The analysis on imputed
prediabetes diagnosis date yielded similar results compared
with that using the diabetes diagnosis date (Fig. 3b). In the
subsequent two sensitivity analyses we excluded participants
with an eGFR below 60ml min−1 [1.73 m2]−1 and participants
with hypomagnesaemia or hypermagnesaemia (Fig. 3). These
analyses yielded similar results as in our main analyses. In the
final analysis, we found that the addition of proton pump
inhibitor use to our analysis on diabetes and prediabetes did
not alter the association (data not shown).
Discussion
In this large population-based cohort, we found that over a
median follow-up of almost 6 years, low serum magnesium
levels are associated with an increased risk of prediabetes,
with comparable risk estimates to that of diabetes.
Furthermore, we found that common genetic variants in
magnesium-regulating genes influence diabetes risk and that
this risk is mediated through serum magnesium levels.
One strength of our study is that we thoroughly investigated
the directionality of the association between serum magnesium
and diabetes. Serum magnesium has already been associated
with diabetes [12, 13]. However, increased renal magnesium
wasting as a result of uncontrolled diabetes could lead to low
serum magnesium levels [30]. This reversed causation may
explain the observed association between serum magnesium
and diabetes. If indeed low serum magnesium levels are only
the result of uncontrolled diabetes, rather than a potential cause,
one would not expect to find an effect of magnesium
supplementation on diabetes risk and there would be no need
to design a randomised controlled trial. Our study provides
more evidence that magnesium may indeed influence diabetes
risk, as we found similar associations for prediabetes as
diabetes. The association with prediabetes is unlikely to be
caused by reversed causation as glucose levels are not high
Total participants in the Rotterdam Study
n=14,926
Eligible participants for current study
n=11,740
Valid glucose measurement at baseline
n=10,147
Valid magnesium measurement at baseline
n=9811
Informed consent for follow-up
n=9752
No diabetes at baseline
n=8555
Subjected to outcome analysis:
diabetes
Normal glucose
at baseline
n=7209 
Subjected to outcome analysis:
prediabetes
Participants lost to follow-up, death or did
not participate in examination round
n=3186 
Prediabetes
at baseline
n=1346
Fig. 1 Flowchart of the study
population. Of the 11,740 eligible
participants, 3185 participants
were excluded because of missing
data in magnesium or glucose
measurements at baseline, no
informed consent or prevalent
diabetes mellitus. This resulted in
a total study population of 8555
participants, which could be
further divided into 7209
participants with normal glucose
level at baseline and 1346
participants with prediabetes at
baseline
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Table 1 Baseline characteristics
of the study population Characteristic Total population
N= 8555
Prevalent
normoglycaemia
N= 7209
Prevalent
prediabetes
N = 1346
Age, years 64.7 (9.7) 64.3 (9.7) 66.6 (9.4)
Women, n (%) 4949 (57.8) 4271 (59.2) 678 (50.4)
Body mass index, kg/m2 27.0 (4.0) 26.7 (3.9) 28.5 (4.4)
Smoking, n (valid per cent)
Never 2647 (31.2) 2279 (31.9) 368 (27.4)
Former 3933 (46.3) 3272 (45.7) 661 (49.3)
Current 1914 (22.5) 1602 (22.4) 312 (23.3)
Alcohol use, n (valid per cent) 7297 (85.9) 6136 (85.8) 1161 (86.6)
Total cholesterol, mmol/l 5.76 (1.01) 5.76 (1.01) 5.74 (1.02)
HDL cholesterol, mmol/l 1.43 (0.41) 1.44 (0.41) 1.33 (0.40)
History of hypertension, n (valid per cent) 5078 (60.1) 4072 (57.2) 1006 (75.2)
History of stroke, n (valid per cent)) 245 (2.9) 202 (2.8) 43 (3.2)
History of CHD, n (valid per cent) 516 (6.1) 409 (5.8) 107 (8.1)
eGFR (CKD-EPI), ml min−1 [1.73 m2]−1 79.7 (14.6) 80.0 (14.4) 78.3 (15.2)
Serum calcium, mmol/l 2.43 (0.10) 2.43 (0.10) 2.44 (0.10)
Serum potassium, mmol/l 4.35 (0.34) 4.36 (0.33) 4.34 (0.36)
Use of diuretics, n (%) 703 (8.2) 528 (7.3) 175 (13.0)
Serum glucose, mmol/l 5.46 (0.58) 5.30 (0.45) 6.32 (0.47)
Serum insulin, pmol/l 83.8 (63.0) 78.6 (56.0) 111.3 (84.8)
Serum magnesium, mmol/l 0.85 (0.06) 0.85 (0.06) 0.84 (0.06)
Hypomagnesaemiaa, n (%) 131 (1.5) 92 (1.3) 39 (2.9)
Hypermagnesaemia, n (%) 185 (2.2) 155 (2.2) 30 (2.2)
Data are presented as n (%), n (valid per cent) or mean (SD)
Values are shown for non-imputed data
n values for certain variables do not necessarilymatch the total cohort number for each category because of missing
data as a result of: (1) no answer provided during interview (smoking status and alcohol use); (2) unavailable
blood pressure measurements during the examination round (history of hypertension); or (3) inability to link the
study database to the General Practitioners’ database or registries and, therefore, not being able to ascertain disease
status (history of stroke and coronary heart disease). For variables with missing data, valid per cent is given
a Serum magnesium ≤0.72 mmol/l
b Serum magnesium ≥0.97 mmol/l
Table 2 Association between serum magnesium levels and incident diabetes and prediabetes
At risk Cases Follow-up HR (95% CI)
Variable (N) (N) (person-years) Model 1 Model 2 Model 3
Diabetes
Per 0.1 mmol/l decrease 8555 806 67,296 1.21 (1.07, 1.37) 1.17 (1.04, 1.32) 1.18 (1.04, 1.33)
No hypomagnesaemia 8424 785 66,421 1.00 (reference) 1.00 (reference) 1.00 (reference)
Hypomagnesaemia 131 21 875 2.12 (1.38, 3.28) 1.80 (1.17, 2.78) 1.79 (1.16, 2.77)
Prediabetes
Per 0.1 mmol/l decrease 7209 1120 54,243 1.14 (1.02, 1.27) 1.13 (1.01, 1.25) 1.12 (1.01, 1.25)
No hypomagnesaemia 7117 1101 53,667 1.00 (reference) 1.00 (reference) 1.00 (reference)
Hypomagnesaemia 92 19 576 1.72 (1.09, 2.71) 1.51 (0.96, 2.37) 1.44 (0.91, 2.27)
Model 1: adjusted for age, age2 , sex
Model 2: model 1+BMI, smoking status, alcohol use and total cholesterol:HDL-cholesterol ratio, history of hypertension, history of stroke and history of
coronary heart disease
Model 3: model 2 + eGFR (CKD-EPI), serum calcium, serum potassium and use of diuretics
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Table 3 Mediation analysis for magnesium-regulating genes
Diabetes
N= 7428
Prediabetes
N= 6267
Gene SNP Effect on serum magnesium levelsa
β, mmol/l (95% CI)
Direct effectb
OR (95% CI)
Indirect effectc
OR (95% CI)
Direct effectd
OR (95% CI)
Indirect effecte
OR (95% CI)
CLDN16 rs9990270 0.001 (−0.001, 0.002) 0.92 (0.83, 1.03) 1.00 (1.00, 1.00) 0.99 (0.90, 1.09) 1.00 (1.00, 1.00)
CLDN19 rs719676 0.002 (0.000, 0.005)* 0.84 (0.74, 0.96)* 1.00 (0.99, 1.00) 0.88 (0.78, 0.98)* 1.00 (0.99, 1.00)
CNNM2 rs3740393 0.005 (0.003, 0.008)* 0.97 (0.82, 1.15) 0.99 (0.98, 1.00)* 1.07 (0.94, 1.23) 1.00 (0.99, 1.00)
FXYD2 rs948100 −0.004 (−0.006, −0.001)* 1.12 (0.94, 1.33) 1.01 (1.00, 1.02)* 1.14 (0.98, 1.32) 1.00 (1.00, 1.01)
SLC41A1 rs823154 0.000 (−0.001, 0.002) 0.94 (0.84, 1.05) 1.00 (1.00, 1.00) 0.95 (0.86, 1.04) 1.00 (1.00, 1.00)
SLC41A2 rs2463021 −0.004 (−0.007, 0.000)* 1.00 (0.82, 1.22) 1.01 (1.00, 1.02)* 0.96 (0.80, 1.14) 1.00 (1.00, 1.01)
TRPM6 rs2274924 −0.004 (−0.006, −0.001)* 1.01 (0.87, 1.16) 1.01 (1.00, 1.02)* 1.07 (0.94, 1.21) 1.00 (1.00, 1.01)
TRPM7 rs8042919 0.002 (−0.001, 0.005) 0.95 (0.78, 1.15) 1.00 (0.99, 1.00) 1.05 (0.90, 1.23) 1.00 (0.99, 1.00)
a Effect of gene on serum magnesium level (mmol/l), per allele increase
bDirect effect (OR) of gene on diabetes, adjusted for serum magnesium levels
c Indirect effect (OR) of gene on diabetes, mediated by serum magnesium levels
d Direct effect (OR) of gene on prediabetes, adjusted for serum magnesium levels
e Indirect effect (OR) of gene on prediabetes, mediated by serum magnesium levels
* p < 0.05
Serum magnesium
levels
(per 0.1 mmol/l decrease)
Diabetes
(fasting glucose > 7 mmol/l;
non-fasting glucose > 11.1 mmol/l)
Log
e
 HOMA-IR
levels
Serum magnesium
levels
(per 0.1 mmol/l decrease)
Impaired fasting glucose
(fasting glucose 6−7 mmol/l;
non-fasting glucose 7.7−11.1 mmol/l)
Log
e
 HOMA-IR
levels
β 0.052
(0.030, 0.074)
β 0.023
(0.000, 0.047)
Direct effect:
OR 1.11 (0.98, 1.26)
Indirect effect:
OR 1.05 (1.03, 1.07)
Direct effect:
OR 1.09 (0.98, 1.22)
Indirect effect:
OR 1.01 (1.00, 1.03)
OR 1.72
(1.53, 1.92)
b
a
OR 2.53
(2.25, 2.85)
Fig. 2 The role of insulin sensitivity in the association between serum
magnesium levels and prediabetes/diabetes. The association was
modelled using a mediation analysis, with insulin resistance calculated
as loge HOMA-IR levels. (a) The association with diabetes was studied in
participants without diabetes at baseline. The direct effect of serum
magnesium levels on incident diabetes was found not to be significant
when adjusting for loge HOMA-IR levels. The indirect effect, which
represents the effect of serum magnesium levels on diabetes as mediated
by loge HOMA-IR levels, was found to be significant. (b) The association
with prediabetes was studied in participants with normal blood glucose at
baseline. The direct effect of serum magnesium levels on incident
prediabetes was found not to be significant when adjusting for loge
HOMA-IR levels. The indirect effect was found to be significant
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enough to cause increased urinary magnesium wasting.
Additionally, we found that magnesium-regulating genes
associate with diabetes risk, further demonstrating that reverse
causation is not likely to play a role, since diabetes status cannot
alter genetic makeup. Another strength of our study is the
detailed classification of diabetes and prediabetes, using a
combination of prospectively gathered data that included the
medical records of hospitals and general practitioners,
electronic linkage with pharmacy dispensing records in the
study area and standardised blood glucose measurements
during visits to the study centre. This comprehensive
assessment reduces potential bias result ing from
misclassification. Furthermore, our study used a mediation
analysis; this type of analysis goes beyond traditional analyses
as it allows for a more causal interpretation of data, when
certain assumptions are met [31]. The limitation of this type
of analysis is directly linked to these assumptions, one of which
is that there is no unmeasured confounding in the relationship
between the mediator and the outcome. This assumption is
difficult to check as unmeasured confounding can always play
a role in observational data. However, we have adjusted our
analysis for many potential confounders, which only slightly
attenuated the effect estimates. Therefore, it is unlikely that the
association between serum magnesium and diabetes risk is due
to residual confounding, as this unknown confounder must be
stronger and more imbalanced than all the confounders used in
the current study. A second limitation of our study is that
participants of the Rotterdam Study are predominantly of
European descent. Previous studies demonstrated a lack of
association between serum magnesium levels and diabetes risk
in black participants [12], but we were unable to stratify on
ethnicity. Another limitation of our study is the use of a single
measurement of serum magnesium. Consequently, we were
unable to study if changes in serum magnesium levels over
time might influence diabetes risk. However, in a previous
study serum magnesium concentrations measured 1 year apart
were found to strongly correlate [32].
In combination with association directionality, we also
studied the pathway by which serum magnesium levels may
influence prediabetes and diabetes risk and found evidence of
a dominant role of insulin resistance. A previous study
demonstrated an effect of serum magnesium levels on insulin
resistance [2]. However, the mediating effect of serum
magnesium levels on diabetes through insulin resistance was
not quantified. We found that approximately 29% of the effect
of serum magnesium levels on diabetes and approximately
13% of the effect on prediabetes is mediated through insulin
resistance. This partial mediation confirms the results of the
Atherosclerosis Risk in Communities (ARIC) study, which
found that the effect of serum magnesium levels on diabetes
risk remained after adjusting for fasting glucose levels [12].
The remaining effect of serum magnesium levels on diabetes
Table 4 Sensitivity analysis
using magnesium and other
electrolytes as determinants
Normal glucose to prediabetes
Determinant HR (95% CI) p value
Serum magnesium (per 0.1 mmol/l decrease) 1.12 (1.01, 1.25) 0.034
Serum sodium (per 1 mmol/l decrease) 1.01 (0.99, 1.03) 0.297
Serum potassium (per 0.1 mmol/l decrease) 1.00 (0.98, 1.02) 0.821
Serum calcium (per 0.1 mmol/l decrease) 1.04 (0.98, 1.11) 0.218
Serum phosphate (per 0.1 mmol/l decrease) 1.03 (0.98, 1.07) 0.216
Model 3 (adjusted for age, age2 , sex, BMI, smoking status, alcohol use, total cholesterol:HDL-cholesterol ratio,
history of hypertension, history of stroke, history of coronary heart disease, eGFR (CKD-EPI), serum calcium,
serum potassium and use of diuretics was used for all analyses
Fully adjusted model
a b
Excluding eGFR < 60 ml min-1 [1.73 m2]-1
Restricting to normomagnesaemia
Fully adjusted model
Excluding eGFR < 60 ml min-1 [1.73 m2]-1
Restricting to normomagnesaemia
Imputed impaired fasting glucose follow-up time
0.8 1.0 1.2 1.4 1.60.8 1.0 1.2
HR HR
1.4 1.6
Fig. 3 Sensitivity analyses. For both the analysis on (a) diabetes and (b)
prediabetes we performed several sensitivity analyses, using the fully
adjusted model (model 3). In the first analysis, we excluded all
participants with an eGFR below 60 ml min−1 [1.73 m2]−1. In the second
analysis, we excluded all participants with hypomagnesaemia or
hypermagnesaemia. For the analysis on prediabetes we performed an
additional sensitivity analyses to study if misclassified prediabetes cases
(i.e. those without a prediabetes diagnosis date) could have influenced our
results
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and prediabetes risk could occur via insulin secretion or
through its impact on insulin signalling [33]. The effect of
magnesium on insulin metabolism and glycaemic control, in
both patients with diabetes and without diabetes, has been
studied in several randomised clinical trials. A meta-analysis
of 370 patients with type 2 diabetes found that oral
magnesium supplementation of 360 mg/day could influence
serum magnesium levels, although not linearly, after a median
of 12 weeks. This oral magnesium supplementation also
significantly lowered fasting glucose levels, but did not
influence long-term glycaemic control [34]. In another trial,
the effect of 16 weeks of 2.5 g magnesium chloride
administration daily was studied in type 2 diabetes patients
with decreased serum magnesium levels at baseline.
Magnesium supplementation significantly increased serum
magnesium concentration and significantly reduced fasting
glucose levels, fasting insulin levels and HbA1c levels
compared with the control group [35]. Furthermore, in obese
patients without hypomagnesaemia but with decreased insulin
sensitivity at baseline, a positive effect of supplementation
with 365 mgmagnesium per day was observed. However, this
supplementation only increased ionisedmagnesium levels and
not total serum magnesium levels [36]. The effect of
magnesium supplementation on insulin sensitivity was less
pronounced in patients with normomagnesaemia. However,
a positive effect could still be observed in these patients,
supporting our finding of a linear association between serum
magnesium levels and prediabetes risk.
We found that five previously identified magnesium-
regulating genes were significantly associated with serum
magnesium levels and that these genes were also associated
with diabetes risk. We, hereby, replicate the findings from
previous studies on the effect of TRPM6, SLC41A2 and
CLDN19 on diabetes risk [20, 21]. The effect of genetic
variation in TRPM6 and SLC41A2 was found to be mediated
through serum magnesium levels. Variation in TRPM6 can
alter serum magnesium levels, as it has an essential role in
magnesium reabsorption within the distal convoluted tubule
[37] and SLC41A2 is important for mediated magnesium
transport across the plasma membrane [38]. CLDN19 was
found to associate with diabetes risk independently from
serum magnesium levels. CLDN19 is highly expressed in
renal tubules where it influences paracellular magnesium
transport. However, CLDN19 has also been found in
extra-renal tissues, including peripheral neurons where it
was found to influence the pore selectivity of tight junctions
[39]. Therefore, a magnesium-independent role for CLDN19
in diabetes risk could be proposed since alterations in tight
junctions have previously been linked with diabetes [40].
Besides confirming the role of these three genes in the
association between magnesium and diabetes, we also
identified new associations between two other magnesium-
regulating genes (CNNM2 and FXYD2) and diabetes risk,
which were also mediated through serum magnesium levels.
CNNM2 is thought to play a role in intracellular magnesium
sensing. However, it is still unclear how this may lead to
alterations in magnesium transport and, thus, alterations in
serum magnesium levels [37]. FXYD2 encodes the γ-subunit
of the Na+–K+-ATPase on the basolateral membrane of the
distal convoluted tubule, where it drives paracellular
magnesium transport through maintenance of the membrane
potential [41]. At present, these findings have little impact on
clinical or population health but they do provide more grounds
for the role ofmagnesium in the pathogenesis of diabetes since
slight alterations in serum magnesium levels, caused by
common genetic variation in magnesium-handling genes,
were found to impact diabetes risk. As expected with common
genetic variants, the observedORswere small. As the effect of
magnesium on prediabetes is less pronounced than its effect
on diabetes, we also expected smaller effects of magnesium-
regulating genes on prediabetes risk. A post hoc power
calculation showed that we had little power (2.9–17.2%) to
detect significant differences in the mediation analysis on
prediabetes; therefore, it is not surprising that we did not find
significant associations with prediabetes for all magnesium-
regulating genes.
Conclusions In conclusion, we found that low serum
magnesium levels are associated with an increased risk of
prediabetes, with similar effect estimates as compared with
diabetes. The effect of serum magnesium on prediabetes and
diabetes risk is partly mediated through insulin resistance.
Furthermore, common genetic variation in magnesium
regulating genes TRPM6, CLDN19, SLC41A2, CNNM2 and
FXYD2 significantly modify the risk of diabetes through
serum magnesium levels. Both findings support a potential
causal role of magnesium in the development of diabetes
and warrant future randomised controlled trials to study the
effect of long-term magnesium supplementation on diabetes
risk.
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